ClinicalTrials.gg
CompletedNCT01569295TugelaUpdated Mar 10, 2020Results posted

Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )

A Phase 3 interventional study of Idelalisib and Rituximab in Chronic Lymphocytic Leukemia, sponsored by Gilead Sciences. Completed at 106 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-10.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
416
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell — 1 open to participants now, 1 under way, none of them phase 3. idelalisib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
2nd of 25
416 · median 102
Started
2012
with 4 others
Phase 3
8 of 25
none open now
Registered
8th of 25
by date
Lead sponsor
19 of 25
Gilead Sciences

Among the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 2nd largest by enrollment, is one of 5 that started in 2012, is one of 8 in phase 3, and was the 8th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

1 of the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About idelalisib

idelalisib: first FDA approval 2014 (ZYDELIG), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the effect of the addition of idelalisib (formerly GS-1101) to bendamustine + rituximab (BR) on progression-free survival (PFS) in participants with previously treated chronic lymphocytic leukemia (CLL)

03

Conditions studied

  • Chronic Lymphocytic Leukemia

Keywords

  • Zydelig
  • CLL
  • CAL-101
  • GS 1101
  • GS-1101
  • PI3K
  • Rituxan
  • Rituximab
  • Bendamustine
  • Leukemia
  • idelalisib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Previously treated recurrent CLL
  • Measurable lymphadenopathy
  • Requires therapy for CLL
  • Has experienced CLL progression \< 36 months since the completion of the last prior therapy

Key Exclusion Criteria:

  • Recent history of a major non-CLL
  • Evidence of an ongoing infection
  • CLL to bendamustine
  • Concurrent participation in another therapeutic clinical trial

NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
416 participants (actual)

Study arms

  • Experimental
    Idelalisib+bendamustine+rituximab

    Participants will receive idelalisib plus bendamustine and rituximab

    Drug: Idelalisib · Drug: Rituximab · Drug: Bendamustine

  • Placebo comparator
    Placebo to match idelalisib+bendamustine+rituximab

    Participants will receive placebo to match idelalisib plus bendamustine and rituximab

    Drug: Rituximab · Drug: Bendamustine · Drug: Placebo to match idelalisib

Interventions

  • Idelalisib 150 mg administered orally twice daily

    Also known as: GS-1101, CAL-101, Zydelig®

  • Rituximab 375 mg/m\^2 on Day 1, then 500 mg/m\^2 every 28 days administered intravenously for a maximum of 6 infusions

    Also known as: Rituxan®, MabThera

  • Bendamustine 70 mg/mg\^2/day on 2 consecutive days every 28 days administered intravenously for a maximum of 12 infusions

    Also known as: Ribomustin, Treanda®

  • DrugPlacebo to match idelalisib

    Placebo to match idelalisib administered orally twice daily

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    PFS was defined as the interval from randomization to the earlier of the first documentation of definitive disease progression or death from any cause. PFS (months) = (minimum (date of disease progression, date of death) - date of randomization + 1)/30.4375.

    Time frame: Up to 84 months

Secondary outcomes

  1. Overall Response Rate (ORR)

    ORR was the percentage of participants who achieved a complete response (CR), CR with incomplete marrow recovery (CRi,) or partial response (PR) and maintained the response for at least 12 weeks. CR was defined as no lymphadenopathy, hepatomegaly, splenomegaly; normal complete blood count; confirmed by bone marrow aspirate \& biopsy. PR was defined as \>1 of the following criteria: a 50% decrease in peripheral blood lymphocytes, lymphadenopathy, liver size, spleen size; plus ≥ 1 of the following: ≥ 1500/μL absolute neutrophil count, \> 100000/μL platelets, \> 11.0 g/dL hemoglobin or 50% improvement for either of these parameters without transfusions or growth factors. CRi was defined as all criteria for CR met but with persistent anemia, thrombocytopenia, neutropenia or a hypocellular bone marrow.

    Time frame: Up to 84 months

  2. Lymph Node Response Rate

    Lymph node response rate was defined as the percentage of participants who achieved a ≥ 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters (SPD) of index lesions.

    Time frame: Up to 84 months

  3. Overall Survival

    Overall survival (OS) was defined as the interval from randomization to death from any cause. Overall survival (months) = (date of death - date of randomization + 1)/30.4375.

    Time frame: Up to 84 months

  4. Complete Response Rate

    Complete response (CR) rate was defined as the percentage of participants who achieved a CR.

    Time frame: Up to 84 months

07

Results

Posted Feb 27, 2018

Participant flow

Participants were enrolled at a total of 110 sites in Australia, New Zealand, Europe, Asia and North America. The first participant was screened on 15 June 2012. The last study visit occurred on 10 June 2019.

Participant flow — Overall Study
MilestoneIdelalisib + Bendamustine + RituximabPlacebo + Bendamustine + Rituximab
Started207209
Long-term follow-up109161
Completed00
Not completed207209
Withdrew: Progressive disease75139
Withdrew: Adverse event3914
Withdrew: Withdrawal by subject2512
Withdrew: Death1915
Withdrew: Physician decision1318
Withdrew: Study terminated by sponsor242
Withdrew: Other reason not specified35
Withdrew: Non-compliance with study drug61
Withdrew: Other anticancer/experimental therapy22
Withdrew: Lost to follow-up11

Outcome measures

PrimaryProgression-Free Survival (PFS)

PFS was defined as the interval from randomization to the earlier of the first documentation of definitive disease progression or death from any cause. PFS (months) = (minimum (date of disease progression, date of death) - date of randomization + 1)/30.4375.

Time frame:
Up to 84 months
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsIdelalisib + Bendamustine + RituximabPlacebo + Bendamustine + Rituximab
Progression-Free Survival (PFS)21.8 (16.5 to 27.8)11.1 (8.9 to 11.1)
Statistical analysis
  • Idelalisib + Bendamustine + Rituximab vs Placebo + Bendamustine + Rituximab · Stratified log-rank test · p = < 0.0001 · Hazard ratio (hr): 0.35 · 95% CI 0.27 to 0.45Hazard Ratio is estimated using Cox proportional hazard model, adjusted for randomization stratification factors.
SecondaryOverall Response Rate (ORR)

ORR was the percentage of participants who achieved a complete response (CR), CR with incomplete marrow recovery (CRi,) or partial response (PR) and maintained the response for at least 12 weeks. CR was defined as no lymphadenopathy, hepatomegaly, splenomegaly; normal complete blood count; confirmed by bone marrow aspirate \& biopsy. PR was defined as \>1 of the following criteria: a 50% decrease in peripheral blood lymphocytes, lymphadenopathy, liver size, spleen size; plus ≥ 1 of the following: ≥ 1500/μL absolute neutrophil count, \> 100000/μL platelets, \> 11.0 g/dL hemoglobin or 50% improvement for either of these parameters without transfusions or growth factors. CRi was defined as all criteria for CR met but with persistent anemia, thrombocytopenia, neutropenia or a hypocellular bone marrow.

Time frame:
Up to 84 months
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsIdelalisib + Bendamustine + RituximabPlacebo + Bendamustine + Rituximab
Overall Response Rate (ORR)70.0 (63.3 to 76.2)45.5 (38.6 to 52.5)
Statistical analysis
  • Idelalisib + Bendamustine + Rituximab vs Placebo + Bendamustine + Rituximab · Cochran-Mantel-Haenszel · p = <0.0001 (Odds ratio,p-value and 95% Confidence Interval(CI) were calculated from Cochran-Mantel-Haenszel(CMH) Chi-square test stratified by stratification factor in EDC(del17p/TP53,immunoglobulin heavy chain variable region(IgHV) mutation and disease status).) · Odds ratio (or): 3.02 · 95% CI 1.98 to 4.62
SecondaryLymph Node Response Rate

Lymph node response rate was defined as the percentage of participants who achieved a ≥ 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters (SPD) of index lesions.

Time frame:
Up to 84 months
Reported as:
Number · percentage of particpants
Lymph Node Response Rate
percentage of particpantsIdelalisib + Bendamustine + RituximabPlacebo + Bendamustine + Rituximab
Lymph Node Response Rate96.9 (93.3 to 98.8)60.9 (53.7 to 67.8)
Statistical analysis
  • Idelalisib + Bendamustine + Rituximab vs Placebo + Bendamustine + Rituximab · Cochran-Mantel-Haenszel · p = <0.0001 (Odds ratio, p-value and 95% CI were calculated from the CMH Chi-square test stratified by stratification factors in EDC (del17p/TP53, IgHV mutation and disease status).) · Odds ratio (or): 28.81 · 95% CI 10.50 to 79.02
SecondaryOverall Survival

Overall survival (OS) was defined as the interval from randomization to death from any cause. Overall survival (months) = (date of death - date of randomization + 1)/30.4375.

Time frame:
Up to 84 months
Reported as:
Median · months
Overall Survival
monthsIdelalisib + Bendamustine + RituximabPlacebo + Bendamustine + Rituximab
Overall Survival56.2 (40.1 to NA)42.6 (35.3 to 54.8)
Statistical analysis
  • Idelalisib + Bendamustine + Rituximab vs Placebo + Bendamustine + Rituximab · Stratified log-rank test · p = 0.098 · Hazard ratio (hr): 0.78 · 95% CI 0.59 to 1.03
SecondaryComplete Response Rate

Complete response (CR) rate was defined as the percentage of participants who achieved a CR.

Time frame:
Up to 84 months
Reported as:
Number · percentage of participants
Complete Response Rate
percentage of participantsIdelalisib + Bendamustine + RituximabPlacebo + Bendamustine + Rituximab
Complete Response Rate4.3 (2.0 to 8.1)0.5 (0 to 2.6)
Statistical analysis
  • Idelalisib + Bendamustine + Rituximab vs Placebo + Bendamustine + Rituximab · Cochran-Mantel-Haenszel · p = 0.011 (Odds ratio, 95% CI and p-value are calculated from the CMH Chi-square test stratified by stratification factors in EDC (del17p/TP53, IgHV mutation and disease status).) · Odds ratio (or): 9.55 · 95% CI 1.19 to 76.81

Adverse events

Collected over First dose up to the last dose date plus 30 days (Up to approximately 67.7 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Idelalisib + Bendamustine + Rituximab89/207 (43%)152/207 (73.4%)199/207 (96.1%)
Placebo + Bendamustine + Rituximab106/209 (50.7%)94/209 (45%)196/209 (93.8%)
Most frequent serious events
Showing 10 of 239
Most frequent serious events
EventIdelalisib + Bendamustine + RituximabPlacebo + Bendamustine + Rituximab
Febrile neutropeniaBlood and lymphatic system disorders45/20710/209
PneumoniaInfections and infestations38/20716/209
PyrexiaGeneral disorders25/20711/209
DiarrhoeaGastrointestinal disorders14/2071/209
SepsisInfections and infestations11/2074/209
NeutropeniaBlood and lymphatic system disorders9/2073/209
AnaemiaBlood and lymphatic system disorders8/2075/209
Lower respiratory tract infectionInfections and infestations7/2075/209
Urinary tract infectionInfections and infestations7/2073/209
Neutropenic sepsisInfections and infestations3/2076/209
Most frequent other events
Showing 10 of 44
Most frequent other events
EventIdelalisib + Bendamustine + RituximabPlacebo + Bendamustine + Rituximab
NeutropeniaBlood and lymphatic system disorders129/207113/209
DiarrhoeaGastrointestinal disorders89/20747/209
PyrexiaGeneral disorders78/20755/209
NauseaGastrointestinal disorders60/20772/209
AnaemiaBlood and lymphatic system disorders54/20748/209
CoughRespiratory, thoracic and mediastinal disorders52/20747/209
FatigueGeneral disorders45/20752/209
ThrombocytopeniaBlood and lymphatic system disorders41/20746/209
Infusion related reactionInjury, poisoning and procedural complications29/20745/209
Upper respiratory tract infectionInfections and infestations37/20721/209

Baseline characteristics

The intent-to-treat (ITT) Analysis Set included all participants randomized in the study regardless of whether study drug was administered and with treatment group designated according to initial randomization.

Age, Continuous
Age, Continuous(years)Idelalisib + Bendamustine + RituximabPlacebo + Bendamustine + RituximabTotal
Mean62 ± 9.263 ± 9.862 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)Idelalisib + Bendamustine + RituximabPlacebo + Bendamustine + RituximabTotal
Female4753100
Male160156316
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Idelalisib + Bendamustine + RituximabPlacebo + Bendamustine + RituximabTotal
Race — White187190377
Race — Black or African American6410
Race — Asian213
Race — Other224
Race — Not Permitted101222
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Idelalisib + Bendamustine + RituximabPlacebo + Bendamustine + RituximabTotal
Ethnicity — Hispanic or Latino459
Ethnicity — Not Hispanic or Latino191188379
Ethnicity — Not Permitted121527
Ethnicity — Missing011
Region of Enrollment
Region of Enrollment(Participants)Idelalisib + Bendamustine + RituximabPlacebo + Bendamustine + RituximabTotal
Romania5611
Hungary242044
United States373370
Czechia9514
United Kingdom272956
Portugal145
Russia221436
Spain141832
Greece112
Canada033
Turkey6612
Belgium3710
Ireland112
Poland172239
Italy10717
Australia8816
France131427
Croatia5914
New Zealand426
08

Study locations

106 sites
  • Clearview Cancer Institute
    Huntsville, Alabama 35805, United States
  • UCLA Medical Center
    Los Angeles, California 90095, United States
  • Stanford Cancer Center
    Palo Alto, California 94035, United States
  • Rocky Mountain Cancer Center
    Denver, Colorado 80218, United States
  • University of Florida
    Gainesville, Florida 32603, United States
  • Winship Cancer Institute at Emory University
    Atlanta, Georgia 30322, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Summit Medical Group, P.A.
    Morristown, New Jersey 07962, United States
  • North Shore University Hospital
    Manhasset, New York 11030, United States
  • Long Island Jewish Medical Center
    New Hyde Park, New York 11042, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10021, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Willamette Valley Cancer Center
    Eugene, Oregon 97477, United States
  • Charleston Hematology Oncology
    Charleston, South Carolina 29414, United States
  • Texas Oncology
    Austin, Texas 78731, United States
  • Texas Oncology PA
    Dallas, Texas 75246, United States
  • Texas Oncology
    Fort Worth, Texas 76104, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
  • Cancer Care Northwest, US Oncology
    Spokane, Washington 99202, United States
  • Virginia Cancer Specialists, PC
    Vancouver, Washington 98684, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • St Vincent's Hospital - Sydney
    Darlinghurst, New South Wales 2010, Australia
  • Gosford Hospital
    Gosford, New South Wales 2250, Australia
  • Princess Alexandra Hospital
    Woolloongabba, Queensland 4102, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Monash Medical Centre - Clayton Campus
    Clayton, Victoria 3168, Australia
  • Sir Charles Gairdner Hospital
    Nedlands, Western Australia 6009, Australia
  • Princess Alexandra Hospital
    Woolloongabba, 4102, Australia
  • Ziekenhuisnetwerk Antwerpen - AZ Stuivenberg
    Antwerpen, 2060, Belgium
  • UZ Gent
    Gent, 9000, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Cancer Care Manitoba
    Winnipeg, Manitoba R3E 0V9, Canada
  • Clinical Hospital "Dubrava"
    Zagreb, 10000, Croatia
  • Klinichki Bolnicki Centar-Zagreb
    Zagreb, 10000, Croatia
  • University Hospital Merkur
    Zagreb, 10000, Croatia
  • Fakultni nemocnice Brno
    Brno, 625 00, Czechia
  • Fakultní nemocnice Hradec Králové
    Hradec Králové, 500 05, Czechia
  • Fakultni nemocnice Ostrava
    Ostrava, 708 52, Czechia
  • Hopital Henri Mondor
    Créteil, 94010, France
  • Centre Jean Bernard - Clinique Victor Hugo
    Le Mans cedex, 72015, France
  • CHRU Lille-Hôpital Claude Huriez
    Lille, 59045, France
  • Centre Léon Bérard - Centre régional de lutte contre le cancer Rhône-Alpes
    Lyon, 69373, France
  • Centre Hospitalier de Mulhouse
    Mulhouse, 68100, France
  • CHU Hôtel-Dieu-Service Hématologie
    Nantes, 44 093, France
  • Centre Hospitalier Lyon Sud
    Pierre Bénite, Pierre Bénite, France
  • Hopital Purpan
    Toulouse, 31059, France
  • Hôpitaux de Brabois
    Vandoeuvre-lés-Nancy, 54511, France
  • G. Genimatas Hospital
    Athens, 11527, Greece
  • University General Hospital of Patras
    Patras, 26500, Greece
  • Semmelweis Egyetem
    Budapest, 1083, Hungary
  • Országos Onkológiai Intézet
    Budapest, 1122, Hungary
  • Debreceni Egyetem Orvos- és Egészségtudományi Centrum
    Debrecen, 4032, Hungary
  • Tallian Gyula utca 20-32
    Kaposvár, 7400, Hungary
  • Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ
    Szeged, 6720, Hungary
  • Mater Misericordiae Hospital
    Dublin, Ireland
  • Spedali Civili di Brescia
    Brescia, 25123, Italy
  • Ospedale Oncologico Regionale A. Businco
    Cagliari, 9121, Italy
  • IRCCS Ospedale San Raffaele
    Milano, 20132, Italy
  • Azienda Ospedaliera Universitaria San Giovanni Battista-Molinette
    Torino, 10126, Italy
  • Szpital Specjalistyczny w Brzozowie
    Brzozow, 36-200, Poland
  • Malopolskie Centrum Medyczne
    Krakow, 30-510, Poland
  • Wojewodzki Szpital Specjalistyczny im. M. Kopernika w Lodzi
    Lodz, 93-510, Poland
  • Samodzielny Publiczny Szpital Kliniczny Nr 1
    Lublin, 20-081, Poland
  • Wojewodzki Szpital w Opolu
    Opole, 43-372, Poland
  • Centralny Szpital Kliniczny MSW w Warszawie
    Warszawa, 02-507, Poland
  • Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie
    Warszawa, 02-781, Poland
  • Hospital Santa Maria
    Lisboa, 1649-035, Portugal
  • "Instituto Portugues de Oncologia do Porto Francisco Gentil (IPOPFG, EPE)
    Porto, 4200-072, Portugal
  • Emergency County Clinical Hospital Brasov
    Brasov, 500152, Romania
  • "Colentina" Clinical Hospital
    Bucharest, 20125, Romania
  • "Fundeni" Clinical Institute
    Bucharest, 22328, Romania
  • Regional Oncology Institute Iasi
    Iasi, 700483, Romania
  • Russian Oncology Research Center (N.N. Blokhin)
    Moscow, 115478, Russian Federation
  • Nizhegorodskaya Regional Clinical Hospital n.a. N.A. Semashko
    Nizhniy Novgorod, 603126, Russian Federation
  • Novosibirsk State Regional Clinical Hospital
    Novosibirsk, Russian Federation
  • Ryazan Regional Clinical Hospital
    Ryazan, 390039, Russian Federation
  • Saratov State Medical University
    Saratov, 410028, Russian Federation
  • Research Institute of Hematology and Blood Transfusion
    St. Petersburg, 193024, Russian Federation
  • State Budgetary Healthcare Institution Volgograd Regional Clinical Oncology Dispensary #1
    Volgograd, 400138, Russian Federation
  • Hospital Universitario Germans Trias i Pujol
    Badalona, Cataluña 08916, Spain
  • Hospital Clinic de Barcelona
    Barcelona, Cataluña 8036, Spain
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, Cataluña 8041, Spain
  • Hospital 12 de Octubre
    Madrid, Madrid, Communidad De 28041, Spain
  • Hospital Universitario Puerta de Hierro
    Majadahonda, Madrid, Communidad De 28222, Spain
  • Hospital Universitario de La Princesa
    Madrid, 28033, Spain
  • Gazi University Medical Faculty Gazi Hospital
    Ankara, 06500, Turkey
  • Ankara University Medical Faculty
    Ankara, 6590, Turkey
  • Istanbul University Istanbul Medical Faculty
    Istanbul, 34093, Turkey
  • Ondokuz Mayis University Faculty of Medicine
    Samsun, 55239, Turkey
  • Birmingham Heartlands Hospital
    Birmingham, B9 5SS, United Kingdom
  • Kent and Canterbury Hospital
    Canterbury, CT1 3NG, United Kingdom
  • University Hospital of Wales
    Cardiff, CF14 4XW, United Kingdom
  • Dorset County Hospital
    Dorchester, DT1 2JY, United Kingdom
  • St. James University Hospital
    Leeds, LS9 7TF, United Kingdom
  • Royal Liverpool University Hospital
    Liverpool, L7 8XP, United Kingdom
  • St Bartholomews Hospital
    London, EC1A 7BE, United Kingdom
  • King's College Hospital
    London, SE5 9RS, United Kingdom
  • Hammersmith Hospital
    London, W12 0NN, United Kingdom

Showing the first 100 of 106 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Zelenetz AD, Robak T, et al. Idelalisib Plus Bendamustine and Rituximab (BR) Is Superior to BR Alone in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of a Phase 3 Randomized Double-Blind Placebo-Controlled Study. American Society ofHematology (ASH) 57th Annual Meeting & Exposition; 5-8 December 2015; Orlando, FL.
  • Barrientos JC, Brown JR, et al. Results of a Randomized Double-Blind Placebo-Controlled Phase 3 study Evaluating Idelalisib in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL and Adverse Prognostic Features. American Society of Clinical Oncology (ASCO) 2016 Annual Meeting; 3-7 June 2016; Chicago, IL.
  • Hillmen, P, Ferra C, et al. Idelalisib in Combination with Bendamustine and Rituximab Improves Overall Survival in Patients with Relapsed/Refractory CLL: Interim Results of a Phase 3 Randomized Double-Blind Placebo-Controlled Study. European Hematology Association (EHA) 21st Annual Meeting; 9-12 June 2016; Copenhagen, Denmark.
  • Zelenetz AD, Brown JR et al. Updated Analysis of Overall Survival in Randomized Phase III Study of Idelalisib in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL. American Society of Hematology (ASH) 58th Annual Meeting & Exposition; 3-6 December 2016; San Diego, CA
  • Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M, Ghia P, Illes A, Jurczak W, Marlton P, Montillo M, Morschhauser F, Pristupa AS, Robak T, Sharman JP, Simpson D, Smolej L, Tausch E, Adewoye AH, Dreiling LK, Kim Y, Stilgenbauer S, Hillmen P. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017 Mar;18(3):297-311. doi: 10.1016/S1470-2045(16)30671-4. Epub 2017 Jan 28. PubMed 28139405 ↗
  • Montillo M, Illes A, Robak T, Pristupa AS, Wach M, Egyed M, Delgado J, Jurczak W, Morschhauser F, Schuh A, Eradat H, Shreay S, Barrientos JC, Zelenetz AD. Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial. Health Qual Life Outcomes. 2019 Nov 15;17(1):173. doi: 10.1186/s12955-019-1232-8. PubMed 31729982 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2012 to primary completion in Jun 2019, 83 months.

Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 83 months is above that.

Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2012
First posted
Apr 3, 2012
StartActual
Jun 15, 2012
Primary completionActual
Jun 10, 2019
CompletionActual
Jun 10, 2019
Results delay requested
May 24, 2016
Results first posted
Feb 27, 2018
Last update
Mar 10, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01569295
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Apr 3, 2012
Start date
Jun 15, 2012
Primary completion
Jun 10, 2019
Completion
Jun 10, 2019
Results posted
Feb 27, 2018
Last update
Mar 10, 2020

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Idelalisib

Start the discussion